Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.85 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.85 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.85 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.62 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9652157 | 1.00 | HTR1A (0.85) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL31197375 | 1.00 | HTR1A (0.85) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL31197364 | 1.00 | HTR1A (0.85) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL15923360 | 1.00 | HTR1A (0.85) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL16916968 | 0.98 | HTR1A (0.82) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL30307405 | 0.98 | HTR1A (0.82) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL17994860 | 0.94 | HTR1A (0.79) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL31197367 | 0.92 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL22390094 | 0.92 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL15929304 | 0.92 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BFERMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2025-01-30 | — | — | US | claimed |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2015-12-17 | — | — | US | claimed |
| EP-2950649-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2014120995-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-08-07 | — | — | WO | claimed |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2025-01-30 | — | — | US | disclosed |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | PHARMA CINQ, LLC (US) | 2024-11-12 | — | — | US | disclosed |
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2021-06-03 | — | — | US | disclosed |
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2021-06-03 | — | — | US | disclosed |
| US-10934284-B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | WELLSTAT THERAPEUTICS CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934284-B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | WELLSTAT THERAPEUTICS CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| CN-108250142-B | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity | 维尔斯达医疗公司 | 2021-01-26 | — | — | CN | disclosed |
| EP-3632426-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2015-12-17 | — | — | US | disclosed |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2015-12-17 | — | — | US | disclosed |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2015-12-17 | — | — | US | disclosed |
| EP-2950649-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2015-12-09 | — | — | EP | disclosed |
| CN-104968200-A | Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity | WELLSTAT THERAPEUTICS CORP | 2015-10-07 | — | — | CN | disclosed |
| WO-2014120995-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120995-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-1997048705-A1 | POTASSIUM CHANNEL BLOCKERS | UNIVERSITY COLLEGE LONDON (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | NOD1, NLRP3, AADAC | HTR1A 3470/4885ADRA1D 3118/4885ADRA1A 2888/4885 |
| US-20250034139-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | HTR1A 977/4885ADRA1D 1703/4885ADRA1A 1394/4885 |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | HTR1A 977/4885ADRA1D 1703/4885ADRA1A 1394/4885 |
| US-12139483-B2 | Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | NOD1, NLRP3, AADAC | HTR1A 3470/4885ADRA1D 3118/4885ADRA1A 2888/4885 |
| US-10934284-B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | AAAS, AADAC, NFKBIA | HTR1A 2335/4885ADRA1D 2341/4885ADRA1A 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.